Of note, however, plasma levels of VEGF-A and Angiopoietin-2 (Ang-2), two well-known key drivers of tumor angiogenesis, alongside tumor neuropilin-1 expression, have been respectively reported as promising predictive and prognostic biomarkers in patients treated with bevacizumab in the phase III AVAGAST trial, investigating the addition of bevacizumab to chemotherapy in advanced GC. This evidence concerns the gene NRP1 and neoplasm.